Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of XmAb7195 in Healthy Volunteers and Subjects with Elevated IgE
NCT02148744Phase 1Completed
- Sponsor
- Xencor
- Start
- May 2014
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in allergic rhinitis (AR), allergic conjunctivitis (AC) and atopic dermatitis (AD) comparing XmAb7195 with Placebo (2 arms). Primary endpoint: Number of adverse events including type and severity at Day 43. Started May 2014; status: completed.
02
Drugs
xmab7195
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02148744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02148744.